 |
Journal articles
In vivo Efficacy of a Dry Powder Formulation of Ciprofloxacin-Copper Complex in a Chronic Lung Infection Model of Bioluminescent Pseudomonas aeruginosa
Abstract : A significant limitation of locally delivered treatments for chronic pulmonary infections is often the short residence time within the airways. Ciprofloxacin (CIP), for example, undergoes rapid absorption from the airway lumen. Previously, we demonstrated that the complexation of CIP with copper (CIP-Cu) reduces its apparent epithelial permeability and pulmonary absorption rate without affecting antimicrobial activity against Pseudomonas aeruginosa grown planktonically or as biofilms. This study aimed to evaluate the in vivo efficacy of CIP-Cu, prepared as a dry powder, in a chronic lung infection model. The powders were prepared by jet milling (CIP-HCl) and by spray drying (CIP-Cu). A bioluminescent strain of P. aeruginosa (PAO1::p16Slux) was used to prepare bacteria-loaded agar beads that were inoculated intratracheally to rats. The dynamics of the infection were monitored using luminometry. The bacteria/beads ratio was optimized to allow the highest luminescence signal and animal survival for 8 days. The efficacy of the treatment was evaluated by luminometry in addition to the end-point (Day 8) where colony counting was performed after lung harvesting. Luminescent P. aeruginosa entrapped in agar beads were useful to monitor the spatial development of the chronic lung infection in rats. The rats were treated with the dry powders in a nose-only inhalation exposure system (NOIES). CIP-Cu and CIP-HCl powders showed similar aerodynamic properties and comparable CIP lung deposition. However, treatment with CIP-Cu significantly (p<0.01) reduced by 4-log the number of CFU of P. aeruginosa per lung in the chronic infection model, whereas CIP-HCl effect was not different from the untreated control group.
Cited literature [50 references]
https://www.hal.inserm.fr/inserm-02615177
Contributor : Frederic Tewes Connect in order to contact the contributor
Submitted on : Friday, May 22, 2020 - 11:24:38 AM
Last modification on : Wednesday, November 3, 2021 - 5:58:34 AM
Contributor : Frederic Tewes Connect in order to contact the contributor
Submitted on : Friday, May 22, 2020 - 11:24:38 AM
Last modification on : Wednesday, November 3, 2021 - 5:58:34 AM
File
In vivo Efficacy - Ciprofloxac...
Files produced by the author(s)